Abstract / Description of output
Anti-tumor necrosis factor α (anti-TNF) therapy has revolutionised the treatment of Crohn’s disease (CD). However, primary nonresponse occurs in an estimated 13-40% of patients1 and secondary loss of response in 23%-46% of patients after 12 months2. A challenging and important aspect of anti-TNF management is therefore to avoid the development of nonresponse, and identify/manage secondary nonresponse if it occurs.
Original language | English |
---|---|
Journal | Clinical Gastroenterology and Hepatology |
Early online date | 5 Oct 2016 |
DOIs | |
Publication status | E-pub ahead of print - 5 Oct 2016 |